Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy

European Journal of Heart Failure

Volumn 15, Issue 6, 2013, Pages 597-598

  Wang, Xuejun ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MLN 273; PROTEASOME; PROTEASOME INHIBITOR; THREONINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VALCADE;

ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HEART DISEASE; HEART FAILURE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE RESEMBLING RESTRICTIVE CARDIOMYOPATHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RESTRICTIVE CARDIOMYOPATHY; UBIQUITINATION;

ANIMALS; BORONIC ACIDS; DIPEPTIDES; FEMALE; HEART; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84878274350     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft069     Document Type: Editorial

References (15)

1. Wang X, Pattison JS, Su H. Posttranslational modification and quality control. Circ Res 2013; 112: 367-381.
2. Herrmann J,Wohlert C, Saguner AM, Flores A, Nesbitt LL, Chade A, Lerman LO, Lerman A. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 2013; doi 10.1093/eurjhf/hfrxxx
3. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO, Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 2007; 101: 865-874.
4. Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, Horak KM, Molkentin JD, Wang X. Proteasome functional insufficiency activates the calcineurin-nfat pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res 2010; 88: 424-433.
5. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
6. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247.
7. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007; 138: 396-397.
8. Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol 2012; 128: 244-247.
9. Day SM. The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol 2013; in press.
10. Wang X, Li J, Zheng H, Su H, Powell SR. Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 2011; 301: H2207-H2219.
11. Tian Z, Zheng H, Li J, Li Y, Su H,Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res 2012; 111: 532-542.
12. Li J, Powell SR, Wang X. Enhancement of proteasome function by pa28a overexpression protects against oxidative stress. FASEB J 2011; 25: 883-893.
13. Li J, Horak KM, Su H, Sanbe A, Robbins J,Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 2011; 121: 3689-3700.
14. Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010; 85: 312-320.
15. Hedhli N, Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 2010; 85: 321-329.